A total of 55.9% of the sample (7462 participants) had a recent AUD claim before or at start of OUD treatment, defined by diagnoses within 6 months of the start of treatment. These patients were less likely to receive agonist therapy than their peers without AUD claims (42.0% [3134 participants] vs 53.9% [3165 participants] for buprenorphine; 4.0% [298 participants] vs 6.3% [369 participants] for methadone). Conversely, they were more likely to receive naltrexone (oral naltrexone, 32.2% [2399 participants] vs 14.3% [837 participants]; extended-release naltrexone, 9.9% [737 participants] vs 6.1% [359 participants]). With regard to sociodemographic characteristics, individuals with recent AUD claims were slightly older (mean [SD] age, 34.9 [12.9] vs 30.8 [13.1] years), more likely to be male (4235 [56.8%] vs 3216 [54.7%] men), less likely to be enrolled in Medicaid (2140 [28.7%] vs 1919 [32.7%] participants), and were more likely to incur multiple alcohol-related events (1967 [26.2%] vs 654 [11.1%] events) (Table 1). Participants with recent AUD claims also had more prescriptions for antidepressants (6156 [82.5%] vs 4374 [74.5%] participants), mood stabilizers (3790 [50.8%] vs 2101 [35.8%] participants), antipsychotics (3521 [47.2%] vs 2417 [41.2%] participants), and benzodiazepines (4359 [57.7%] vs 3193 [42.2%] participants) than participants without AUD claims.
